Stockwinners Market Radar for May 30, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EDT Flex director sells $2.65M in common stock - In a regulatory filing, Flex disclosed that its director Michael Capellas sold 78.9K shares of common stock on May 28th in a total transaction size of $2.65M.

20:27 EDT Inari Medical director sells $3.0M in common stock - In a regulatory filing, Inari Medical disclosed that its director William Hoffman sold 60K shares of common stock on May 28th in a total transaction size of $3.0M.

20:12 EDT Cathie Wood's ARK Investment bought 1.5M shares of UiPath today

19:18 EDT Caesars director buys $319.6K in common stock - In a regulatory filing,Caesars disclosed that its director Michael Pegram bought 10K shares of common stock on May 29th in a total transaction size of $319.6K.

19:11 EDT General Motors exec sells $6.52M in common stock - In a regulatory filing, General Motors disclosed that its president Mark Reuss sold 150K shares of common stock on May 28th in a total transaction size of $6.52M.

18:30 EDT Novartis says Phase III data confirm efficacy, safety of oral remibrutinib - Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase inhibitor, in chronic spontaneous urticaria. In the pivotal Phase III studies, REMIX-1 and REMIX-2, remibrutinib treatment showed significant symptom improvement early, which was sustained up to Week 52, in patients with CSU who remained symptomatic despite second-generation H1-antihistamine use1. These data are being presented at the 2024 European Academy of Allergy and Clinical Immunology Congress in Valencia, Spain, May 31-June 3. "A large majority of people with CSU are living with uncontrolled and debilitating symptoms, often trying to manage the condition by cycling through antihistamines at higher doses with no lasting respite, impacting heavily on their day-to-day lives," said Martin Metz, Professor of Dermatology, Charite - Universitatsmedizin Berlin, Germany. "Remibrutinib has become an important investigational treatment for CSU as it blocks the BTK cascade and inhibits the release of histamine. These data show that remibrutinib has the potential to offer patients and physicians a well-tolerated oral treatment that provides early and lasting efficacy."

18:06 EDT Blueprint Medicines announces avapritinib presentations at EAACI/EHA meetings - Blueprint Medicines "announced multiple upcoming datasets across two key conferences that reinforce the significant real-world burden of systemic mastocytosis, and highlight the durable clinical outcomes of AYVAKIT/AYVAKYT, or avapritinib, across the spectrum of the disease. The presentations, which build on over a decade of pioneering research with clinical experts and patient advocates, will be reported at the following meetings: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, May 31 to June 3 and European Hematology Association 2024 (EHA24) Hybrid Congress, June 13 to 16." "Our data reinforce the efficacy and safety of prolonged durations of AYVAKIT therapy, and highlight the urgency to diagnose and treat patients living with systemic mastocytosis," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "Based on unprecedented clinical datasets and the strength of our ongoing commercial launches in the U.S. and Europe, we have made significant progress toward establishing AYVAKIT as the global standard of care. We look forward to continued collaboration with the SM community to redefine what 'well-controlled' means for patients across the spectrum of the disease."

18:01 EDT Samsara CEO sells $3.63M in common stock - In a regulatory filing, Samsara disclosed that its CEO Sanjit Biswas sold 96K shares of common stock on May 28th in a total transaction size of $3.63M.

17:53 EDT HashiCorp reports Q1 total RPO $748.5M vs. $635.3M last year

17:48 EDT Threads' new 'TweetDeck' style' desktop redesign debuts globally - In a post on Threads, Instagram head Adam Mosseri announced that starting today the roll out the new threads.net on desktop globally. begins.."We're starting to roll out the new threads.net on desktop globally, so you can customize and personalize what you see. We have a lot of great ideas to make this the best website to share ideas, so stay tuned for more and let us know if you have any suggestions " Reference Link

17:23 EDT Costco sees FY24 capital expenditures $4.3B-$4.5B - Says $1.50 hot dog price is safe. Says CEO transition has been seamless. Says average transaction was up. Says plans to open 12 new locations in FY24. Says as inflation has leveled off, consumers are spending more on discretionary items. Says sees significant runway to open new warehouses in the U.S. Says technology will be a key priority going forward. Comments and guidance taken from Q3 earnings conference call.

17:09 EDT RTX awarded $301.76M Navy contract modification - RTX was awarded a $301.76M modification to a previously awarded fixed-price-incentive, cost-plus-incentive-fee advanced acquisition contract. This modification procures Lot 19 long-lead time materials as well as the manufacture, assembly, inspection, acceptance, and delivery of 108 conventional takeoff and landing F135 propulsion systems, 27 short takeoff and vertical landing F135 propulsion systems, and 13 Carrier Variant F135 propulsion systems. Additionally, this effort provides global spares requirements to include spare engines, power modules, and other hardware supporting the Navy, Air Force, Marine Corp, non-U.S. Department of Defense participants and Foreign Military Sales customers. Work is expected to be completed in June 2027. Naval Air Systems is the contracting activity.

16:53 EDT Biogen granted marketing authorization for Qalsody by EC - Biogen announced the European Commission, or EC, has granted marketing authorization under exceptional circumstances and maintained orphan designation for Qalsody for the treatment of adults with amyotrophic lateral sclerosis, or ALS, associated with a mutation in the superoxide dismutase 1 gene, or SOD1-ALS. Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease, or MND.

16:50 EDT OncoCyte announces VitaGraft Kidney data published in NEJM - Oncocyte announced that data regarding its lead product VitaGraft Kidney was published in the New England Journal of Medicine. Oncocyte's Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection, or AMR, a leading cause of kidney allograft failure. VitaGraft Kidney measures the amount of DNA in transplant patients' blood that comes from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA testing and is widely used in clinical practice today. In this study, Oncocyte's proprietary diagnostic test using droplet-digital PCR was able to identify responders and non-responders to felzartamab, showing, "a decrease in dd-cfDNA fractions at week 12 and week 24." The study points to new clinical utilities for VitaGraft Kidney beyond the Company's currently approved and reimbursed indication of for cause testing. Both therapeutic efficacy and recurrence monitoring are potential new use cases for dd-cfDNA testing. Both utilities would be expected to require multiple tests during the active management phase, when a drug is being given, and long-term to help doctors watch for AMR recurrence.

16:45 EDT Affinity Bancshares Inc trading resumes

16:43 EDT Marvell reports Q1 adjusted gross margin 62.4% - Reports GAAP gross margin 45.5%.

16:42 EDT Phreesia reports AHSCs up 23% from last year - The company states: "Average number of healthcare services clients, or AHSCs, was 4,065 in the quarter, up 23% year-over-year. Healthcare services revenue per AHSC was $18,243 in the quarter, down 3% year-over-year. Total revenue per AHSC was $24,900 in the quarter, down 2% year-over-year."

16:40 EDT NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO - NextCure protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology ASCO Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor ICI naive and refractory microsatellite stable, MSS/microsatellite instability-low , MSI-L, colorectal cancer CRC and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center."While MSS/MSI-L CRC and ovarian cancer are difficult to treat and recalcitrant to immunotherapy, the combination of NC410 and pembrolizumab demonstrated clinical activity against both tumor types. MSS/MSI-L CRC study subjects who achieved clinical benefit of partial responses or stable disease by the first scan at 9 weeks maintained continued disease control with a median duration of 5.5 months, which is clinically meaningful for this patient population," said Michael Richman NextCure's President and chief executive officer. "In addition, biomarker data support the proposed mechanism of action of NC410 in remodeling the ECM, enhancing infiltration and activation of immune cells in the TME. While the focus of the current presentation is on the targeted CRC patient population, we look forward to reporting the results from the ongoing ovarian cancer cohort expansion later this year."

16:39 EDT Guess down 2% at $22.90 after Q1 results, below-consensus Q2 guidance

16:35 EDT EQT Corporation exec Jordan sells 35,000 common shares - In a regulatory filing, EQT Corporation executive VP William Jordan disclosed the sale of 35,000 common shares of the company on May 29 at a price of $40.72 per share.

16:31 EDT Momentus discloses Nasdaq listing deficiency notice - Momentus "announced that it received notice from the Nasdaq Capital Market LLC notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed with the U.S. Securities and Exchange Commission the Company's Form 10-Q for the period ended March 31, 2024, and because the Company has not filed its Form 10-K for the year ended December 31, 2023. This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company's common stock will be subject to delisting from Nasdaq."

16:30 EDT Collective Audience gets added Nasdaq notice, cites lengthy de-SPAC transaction - Collective Audience has received an additional notification from the listing qualifications department of The Nasdaq Stock Market. Similar to the previous notifications announced on April 25, the new notification has no immediate effect on the continued listing of the company's common stock on the Nasdaq Global Market. In the new notification, Nasdaq indicated that the company is not in compliance with the continued listing requirements regarding the timely filing of its quarterly report on Form 10-Q for the quarter ended March 31 The company has until June 24 to submit a plan to regain compliance. However, the company anticipates it will file the Form 10-Q ahead of the June deadline. "Like with the delay in our Form 10-K for 2023, the delay in filing our 10-Q for the first quarter of this year is due to the lengthy de-SPAC transaction we completed at the end of last year and the additional time we need to complete the related accounting," commented Collective Audience CEO, Peter Bordes. "Our objective is to use this time to set the company on a solid reporting foundation going forward, and we appreciate the additional time Nasdaq has allowed to complete this process and to regain compliance." "As we've worked to complete this accounting process, we have also continued to advance the deployment of our IP, refocused specifically on audience-based performance advertising and media," continued Bordes. "This has included the official launch of our innovative and groundbreaking AdTech platform, AudienceDesk powered by AudienceCloud ."

16:27 EDT Nordstrom falls 7% to $19.52 after Q1 EPS misses estimates

16:25 EDT Veeva falls 8% to $179 after Q1 results and updated FY25 guidance

16:24 EDT Orrstown Financial and Codorus Valley get shareholder approvals for merger - Orrstown Financial Services (ORRF), the parent company of Orrstown Bank, and Codorus Valley Bancorp(CVLY), the parent company of PeoplesBank, A Codorus Valley Company, today announced that they each received shareholder approval for the previously announced merger of equals. At a special meeting of shareholders held on May 30 odorus Valley's shareholders approved the merger of Codorus Valley with and into Orrstown, with Orrstown as the surviving corporation the Agreement and Plan of Merger, dated as of December 12, 202 by and between Orrstown and Codorus Valley, and the compensation payable to the named executive officers of Codorus Valley in connection with the Merger. At a special meeting of shareholders held on May 30 Orrstown shareholders approved the issuance of shares of Orrstown common stock to Codorus Valley shareholders pursuant to the Merger Agreement.

16:22 EDT Veeva reports Q1 subscription services revenue up 29% at $534M

16:18 EDT Gyre Therapeutics gets IND okay from China's NMPA to evaluate F230 for PAH - Gyre Therapeutics announced that the Center for Drug Evaluation CDE of China's National Medical Products Administration NMPA has approved Gyre Pharmaceuticals' ( Investigational New Drug or IND, application for F230 tablets, a selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension or PAH. F230 was originally licensed from Eisai through Gyre's indirect majority stockholder, GNI Group Ltd. "PAH is a rare disease and a progressive, life-threatening disorder that represents a significant unmet need with no known cure," said Han Ying, Ph.D., Chief Executive Officer of Gyre. "Through Gyre Pharmaceuticals, we are committed to advancing F230 through clinical development with the ultimate goal of improving patient outcomes and enhancing the quality of life for those affected by this devastating condition."

16:16 EDT APCU/Center Parc Credit Union to acquire Affinity Bank - Atlanta Postal Credit Union, Georgia's oldest credit union and the largest postal credit union in the United States, along with its community-based subsidiary, Center Parc Credit Union, and Affinity Bancshares, announced that APCU has entered into a definitive agreement pursuant to which the credit union will acquire Covington, Georgia-based Affinity Bank, National Association, a wholly-owned subsidiary of Affinity. The transaction is structured as a purchase and assumption agreement whereby APCU will acquire Affinity Bank by purchasing substantially all assets and assuming substantially all liabilities of Affinity Bank in an all-cash transaction. Once the acquisition is complete, APCU/Center Parc will continue to operate Affinity Bank's locations in Newton County and Northwest Atlanta.

16:12 EDT VF Corp. names Sun Choe as Global President of Vans - VF Corporation "announced that Michelle "Sun" Choe has been appointed Global Brand President, Vans(R), beginning in late July. Sun is a highly accomplished apparel industry executive with nearly three decades of experience leading design and merchandising for renowned global brands, including lululemon, Marc Jacobs, West Elm, Madewell, Urban Outfitters, Levi's and the Gap."

16:10 EDT Galapagos and Adaptimmune in clinical collaboration agreement for uza-cel - Galapagos (GLPG) and Adaptimmune Therapeutics ( ADAP) announced that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy uza-cel, targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform. The Adaptimmune sponsored Phase 1 SURPASS trial with centrally manufactured uza-cel has shown encouraging results in head & neck cancer with an overall response rate of 80%. Initial in vitro results suggest that uza-cel, produced on Galapagos' decentralized manufacturing platform, yields early phenotype T-cells that could improve efficacy and durability compared to uza-cel centrally manufactured on Adaptimmune's platform.2 In addition, Galapagos' decentralized manufacturing platform offers the potential for the delivery of fresh, fit cells with a vein-to-vein time of seven days in a patient population in which rapid access to treatment is vital.

16:09 EDT PagerDuty board authorizes $100M share repurchase program - PagerDuty announced that its Board of Directors has authorized a share repurchase program for up to $100M of common stock. "We believe that our business is well positioned for growth and the continuation of meaningful free cash flow," said Howard Wilson, Chief Financial Officer, PagerDuty. "This share repurchase program signals our desire to manage share dilution and reflects the confidence of the Board and management team in our strategy."

16:06 EDT Ultragenyx: Study of DTX401 Gene Therapy for GSDIa achieves primary endpoint - Ultragenyx Pharmaceutical announced positive topline results from the Phase 3 GlucoGene stud yor NCT05139316, evaluating DTX401, an investigational gene therapy for the treatment of patients aged eight years and older with glycogen storage disease type Ia or GSDIa.The study achieved its primary endpoint, demonstrating that treatment with DTX401 resulted in a statistically significant and clinically meaningful reduction in daily cornstarch intake compared with placebo at Week 48. The mean percent reduction was 41.3% in the DTX401 group compared with 10.3% in the placebo group at Week 48.."This is an incredible milestone for the DTX401 program. These clinically important and statistically significant results are consistent with our Phase 1/2 findings, and the continued improvement in these treated patients reflects the acquired ability to break down glycogen as a source of endogenous glucose from their treated livers," said Eric Crombez, M.D., chief medical officer at Ultragenyx. A treatment that can improve these daily concerns for people with GSDIa without significant risks is essential." These results will be discussed with regulatory authorities to support a marketing application in 2025.

16:02 EDT Pioneer Power receives Nasdaq listing deficiency notice - Pioneer Power announced that on May 24, 2024, the Company received a delinquency notification letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to have timely filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and its continued delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023, with the Securities and Exchange Commission. The 10-Q Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. The 10-Q Notice provides that the Company has until June 17, 2024 to submit a plan to regain compliance with respect to the delinquent reports.

15:39 EDT Digital Health Acquisition Corp trading resumes

15:18 EDT Summit Therapeutics, Akeso higher after HARMONi-2 trial met endpoint - Shares of Summit Therapeutics (SMMT) are up $6.67, or 227%, to $9.61 and have been halted several times for volatility after the company and partner Akeso (AKESF) reported that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival, or PFS. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, whose tumors have positive PD-L1 expression.

15:00 EDT Summit Therapeutics trading resumes

14:49 EDT Summit Therapeutics to resume trading at 3 pm ET - Summit Therapeutics is scheduled to resume trading at 3 pm ET, with quotation set to resume at 2:55 pm ET, according to Nasdaq.

14:31 EDT Summit Therapeutics reports Phase 3 HARMONi-2 trial met primary endpoint - Summit Therapeutics announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival, or PFS. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, whose tumors have positive PD-L1 expression. HARMONi-2 is a single region, multi-center, double-blinded Phase III study conducted in China sponsored by Akeso, Inc. with data generated and analyzed by Akeso. At a prespecified interim analysis conducted by an independent Data Monitoring Committee, ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS by blinded independent central radiology review committee, or BICR, compared to pembrolizumab. The PFS benefit was demonstrated across clinical subgroups, including those with PD-L1 low expression, PD-L1 high expression, squamous and non-squamous histologies, as well as other high-risk patients. "There are no known Phase III clinical trials in NSCLC which have shown a statistically significant improvement compared to pembrolizumab in a head-to-head setting. The Phase III HARMONi-2 study, along with the approval of ivonescimab in China in combination with chemotherapy based on the results of the HARMONi-A trial, provides clear evidence supporting the purposefully engineered, differentiated mechanism of action of ivonescimab, a PD-1 / VEGF bispecific antibody evidencing cooperative binding characteristics, and its opportunity to improve upon the existing standards of care for solid tumors," the company stated.

13:53 EDT Musk says no talks held for role in Trump presidency - Tesla CEO Elon Musk said via Twitter, "There have not been any discussions of a role for me in a potential Trump presidency."

13:47 EDT FAA says Boeing developed roadmap to fix safety, quality-control issues - The Federal Aviation Administration said it "will continue to hold Boeing (BA) accountable after reviewing the company's roadmap to fix its systemic safety and quality-control issues." Administrator Mike Whitaker made the comments following a three-hour meeting with senior Boeing leaders at FAA headquarters. In February, Whitaker directed Boeing to develop an action plan to set a new standard for safety and how the company does business following the January 5 Alaska Airlines Boeing 737 MAX door plug incident. The company has developed this proposal over the last 90 days, with input from the FAA. Boeing senior leadership met with the FAA this morning to present the roadmap and discuss future implementation. Boeing is also now required to have a mandatory Safety Management System, which will ensure a structured, repeatable, systematic approach to identify hazards and manage risk. The FAA added that it will continue its enhanced oversight of Boeing and its suppliers, including more safety inspectors in the Boeing and Spirit AeroSystems (SPR) facilities. Reference Link

13:38 EDT Summit Therapeutics trading halted, news pending

13:16 EDT BAE Systems selected to build OCX for NOAA's GeoXO constellation - BAE Systems has been selected to build the Ocean Color Instrument for the National Oceanic and Atmospheric Administration's Geostationary Extended Observations satellite constellation. With the selection, BAE Systems is now contracted to build all three hyperspectral instruments for the mission, including OCX, the GeoXO Sounder, and the Atmospheric Composition Instrument. GeoXO is expected to begin operations in the early 2030s and continue operating through 2055.

12:42 EDT Dogness Internationa trading halted, volatility trading pause

12:33 EDT Toyota recalls 102,000 Toyota Tundra, Lexus LX vehicles - Toyota said it is conducting a safety recall involving certain model year 2022-2023 Toyota Tundra and Lexus LX vehicles in North America. Approximately, 102,000 Toyota and Lexus branded vehicles are involved in this recall in the U.S. "There is a possibility that certain machining debris may not have been cleared from the engine when it was produced. In the involved vehicles, this can lead to potential engine knocking, engine rough running, engine no start and/or a loss of motive power. A loss of motive power while driving at higher speeds can increase the risk of a crash," the company said in a statement.

12:20 EDT Sophia Genetics launches SOPHia UNITY to accelerate cancer research - SOPHiA GENETICS announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care, the company said in a statement. "At SOPHiA GENETICS, we have mastered the challenge of harmonizing and connecting genomic data and have the capabilities to do the same with other modalities through our CarePath(TM) module," said Jurgi Camblong, PhD., Co-founder and CEO of SOPHiA GENETICS. "SOPHiA UNITY will usher in the next era of precision medicine innovation by bringing together best-in-class institutions that are committed to the advancement of oncology research and the use of data-driven medicine. We are extremely optimistic about the insights this collective intelligence network will generate to further our shared goal." SOPHiA GENETICS announced that the first member to join SOPHiA UNITY is Memorial Sloan Kettering Cancer Center.

12:06 EDT Tesla hits back at Glass Lewis in letter to shareholders - In a letter to shareholders on Wednesday, Tesla responded to Glass Lewis' filing on its upcoming shareholder meeting. Tesla reproached Glass Lewis for urging shareholders to reject CEO Elon Musk's $55B pay plan. Tesla, which accused the firm of "scaremongering," said Glass Lewis "omits key consideration, uses faulty logic, and relies on speculation and hypotheticals." In the letter to shareholders titled "What Glass Lewis Got Wrong About Tesla," the company wrote "Glass Lewis may believe that [Musk] should have done so with more 'focus,' but the fact is that Tesla's performance speaks for itself."

12:04 EDT Kohl's falls -25.8% - Kohl's is down -25.8%, or -$7.03 to $20.22.

12:02 EDT HP Inc. rises 16.7% - HP Inc. is up 16.7%, or $5.47 to $38.27.

12:00 EDT Foot Locker rises 22.9% - Foot Locker is up 22.9%, or $5.15 to $27.67.

11:37 EDT Netflix working on animated 'Minecraft' series - Netflix (NFLX) announced it is working on a new animated series based on Mojang's "Minecraft" video game franchise, in celebration of the original game's fifteenth anniversary. The Fly notes that Mojang is owned by Microsoft (MSFT). Reference Link

11:05 EDT Fitell Corp trading resumes

10:54 EDT Orange Bank & Trust promotes Anthony Pili to CIO - Orange Bank & Trust Company announced that Senior Vice President, Anthony Pili will serve as Chief Innovation Officer, a newly created position responsible for ensuring the Bank remains a leader in providing its clients with the latest in banking technology. In his role as Director of Cash Management, Pili has helped lead Orange Bank & Trust to be a technology leader in digital banking and payments.

10:41 EDT Bank OZK reiterated guidance in conversations with investors - In a regulatory filing, Bank OZK notes that on May 29, the company's management received inquiries regarding a recently published analyst research report, and in conversations with investors management provided information on two loans, the "San Diego Life Science Project" loan and the "Atlanta Mixed Use Project" loan. In both cases, management stated that it "is confident in the project." During the conversations with investors, management referred to its April 17 "Management Comments" document and reiterated the guidance contained therein, the filing noted. Reference Link

10:27 EDT Dollar General seeing promotional levels similiar to 2019 - Says shrink trending worse than previously expected. Comments taken from Q1 earnings conference call.

10:25 EDT Dollar General sees customers continuing to be price sensitive

10:18 EDT Addex Therapeutics Ltd - ADR trading resumes

10:12 EDT CFPB opens public inquiry into rising mortgage closing costs - The Consumer Financial Protection Bureau today launched a public inquiry into "junk fees that are increasing mortgage closing costs." The CFPB "wants to understand why closing costs are increasing, who is benefiting, and how costs for borrowers and lenders could be lowered." According to a CFPB analysis, the closing costs borrowers pay in connection with a mortgage have "risen steeply" in recent years. "From 2021 to 2023, median total loan costs for home mortgages increased by over 36%. The unavoidable fees borrowers must pay at closing can strain household budgets and families' ability to afford a down payment. The fees may also limit the ability of lenders to offer competitive mortgages because they have to absorb the higher costs or pass them on to borrowers," the agency said in a statement. Companies involved in mortgage closings include Fidelity National (FNF), First American (FAF), Rocket Companies (RKT), UWM Holdings (UWMC) and Mr. Cooper (COOP). Reference Link

10:09 EDT Cansortium, RIV Capital enter definitive agreement for business combination - Cansortium (CNTMF) and RIV Capital (CNPOF) announced that they have entered into a definitive arrangement agreement pursuant to which Cansortium will acquire all of the issued and outstanding Class A common shares of RIV Capital in exchange for Cansortium Shares. Under the terms of the Arrangement Agreement, RIV Capital shareholders will receive 1.245 of a common share of Cansortium in exchange for each RIV Capital Share held. Upon closing of the Transaction, shareholders of Cansortium are expected to hold approximately 51.25% of the combined business of Cansortium and RIV Capital and the RIV Capital Shareholders and The Hawthorne Collective, together, are expected to hold approximately 48.75% of the Combined Company, each on a fully diluted basis. Key Transaction Highlights: Positioned in Key U.S. Markets: The Combined Company will be geographically diversified across the eastern U.S., spanning four key states, positioning the Combined Company to cover approximately 25% of the U.S. population. These limited license markets in which the Combined Company is expected to hold a strong position have well-staged regulatory catalysts in the near and medium term. Bolstering Balance Sheet: The Combined Company is expected to be well capitalized with a pro forma cash balance of approximately US$74 million as of March 31, 2024, in a capital scarce environment, in order to enable the Combined Company to fund highly accretive growth. The Hawthorne Collective's intended exchange of its existing convertible notes in RIV Capital for a new class of non-voting exchangeable shares of Cansortium will eliminate US$175 million of debt, which is expected to fundamentally transform the Combined Company's balance sheet. Operational Efficiencies: Cost synergy opportunities are estimated to be approximately US$5-10 million annually over the next few years, which are expected to be realized from anticipated cultivation, processing and operating efficiencies, corporate integration and eliminating duplicative public company costs in the Combined Company. Strategic Partnerships: Strategic relationship with The Scotts Miracle-Gro Company through its investment in RIV Capital via its wholly-owned subsidiary, The Hawthorne Collective and through innovative growing products sold by its wholly-owned subsidiary, The Hawthorne Gardening Company. The Hawthorne Collective intends to exchange its existing convertible notes in RIV Capital for a new class of non-voting exchangeable shares of Cansortium at closing, further strengthening and reinforcing its relationship with the Combined Company. Scalable Talent-Base: Expanded talent-base through the combination of Cansortium and RIV Capital management and operating personnel. The Combined Company will seek to leverage Cansortium's operating expertise and best practices across its footprint. Upon closing of the Transaction, the Combined Company is expected to operate in four of the largest states by population in the U.S. - Florida, New York, Texas, and Pennsylvania - creating a strategic operating footprint with significant potential growth opportunities in the years ahead. Operations in these states will be comprised of 8 cultivation and processing facilities and 42 retail dispensaries. The Combined Company will operate under the Cansortium name and the Cansortium Shares will continue to trade on the Canadian Securities Exchange under the symbol "TIUM.U" and on the OTCQB Venture Market under the symbol "CNTMF". Upon closing of the Transaction, it is expected that the Combined Company will be headquartered in Tampa, Fla., which is the current location of Cansortium's corporate offices, and Robert Beasley, the current Chief Executive Officer of Cansortium, will act as CEO of the Combined Company.

10:03 EDT Kohl's falls -24.6% - Kohl's is down -24.6%, or -$6.71 to $20.54.

10:02 EDT UiPath falls -34.4% - UiPath is down -34.4%, or -$6.29 to $12.01.

10:02 EDT Best Buy rises 12.0% - Best Buy is up 12.0%, or $8.60 to $80.50.

10:00 EDT Foot Locker rises 31.8% - Foot Locker is up 31.8%, or $7.17 to $29.69.

09:50 EDT Kohl's falls -23.2% - Kohl's is down -23.2%, or -$6.33 to $20.91.

09:49 EDT C3.ai rises 13.4% - C3.ai is up 13.4%, or $3.21 to $27.12.

09:47 EDT Foot Locker rises 24.9% - Foot Locker is up 24.9%, or $5.61 to $28.13.

09:32 EDT Home Depot names Jordan Broggi EVP of customer experience, president of online - The Home Depot appointed Jordan Broggi as executive vice president of customer experience and president of online, effective June 3, 2024. In the role of EVP of customer experience, he will be responsible for leading the vision, design, and development of new and innovative solutions to drive an experience for the millions of customers who turn to The Home Depot for their home improvement projects in stores, online, or on mobile devices. He will also retain leadership of the company's online business, overseeing online operations, merchandising strategy and customer experience for The Home Depot's digital properties. Broggi has been with The Home Depot for 11 years, most recently as senior vice president and president of online. Matt Carey, who was most recently EVP of customer experience, will retire from The Home Depot on December 31, 2024, after 16 years with the company.

09:28 EDT Home Depot customer experience VP Matthew Carey to retire, effective December 31 - In a regulatory filing, Home Depot announced that on May 24, Matthew Carey informed the company that he will be retiring from the company, effective December 31, 2024. Effective June 3, 2024, he will no longer serve in his current role of Executive Vice President - Customer Experience, but he will remain an Executive Vice President and serve in an advisory capacity until his retirement at the end of December. There has been no change to Carey's compensation or other terms of employment in connection with his anticipated retirement, Home Depot said.

09:25 EDT Talen Energy commences tender offer to repurchase up to $600M of common stock - Talen Energy announced earlier that it has commenced a modified "Dutch auction" tender offer to purchase for cash up to an aggregate purchase price of $600M and, at the company's option, up to an additional $12M, of its common stock at a price per share not less than $116.00 and not greater than $122.00, less any applicable withholding taxes and without interest, using available cash on hand. The Tender Offer is part of the company's recently upsized $1B share repurchase program that was approved by its Board of Directors earlier this month. On May 28, 2024, the closing price of the Common Stock was $113.60 per share. The Tender Offer is subject to certain terms and conditions. "This tender offer reflects our confidence in the future outlook of our business, the strength of our operations and the value created by recent strategic transactions related to the Company's sale of its ERCOT generation portfolio and the Cumulus data center campus," said Mac McFarland, President and CEO. "Our strong cash flows, balance sheet and operational performance enable us to undertake this transaction while also preserving flexibility for further shareholder returns in the future." The Tender Offer will expire at 5:00 PM, New York City time, on June 27 unless extended or terminated. Goldman Sachs & Co. LLC is acting as dealer manager for the Tender Offer.

09:22 EDT Biotricity to launch direct-to-patient cardiac screening service HeartSecure - Biotricity announced plans for a direct-to-consumer program, HeartSecure, to support the 127M Americans at risk for heart disease. HeartSecure offers the first-of-its-kind, home-based cardiac screening service, empowering individuals to proactively check their heart health from the comfort of their homes. When launched, this groundbreaking home-based cardiac screening service will be a significant milestone for Biotricity, positioning the company for increased growth and market penetration in the $1.05B Home Heart Health market.

09:17 EDT MetLife names Shurawl Sibblies chief human resources officer - MetLife (MET) announced that Shurawl Sibblies will join the company as executive vice president and chief human resources officer, effective August 1. She will report to president and CEO Michel Khalaf and become a member of the executive leadership team. Sibblies comes to MetLife from American Express (AXP), where she was executive vice president and colleague strategic partner leading talent, organizational and leadership development strategies for several businesses and functions. Her scope included the company's consumer business, international markets, innovation units and the enterprise functions.

09:15 EDT Home Bancorp appoints Mark Herpin as COO - Home Bancorp added Mark Herpin to its executive management team as Senior EVP and COO. Herpin joins the company with over 20 years of banking experience in various senior leadership positions including technology, finance, and mergers and acquisitions with First Horizon where he most recently served as Senior Vice President and Director of Strategic Data Solutions. During his time at First Horizon, Herpin also served as Deputy Chief Information Officer, Director of Enterprise Data Management, Director of Business Intelligence, and Financial Planning Manager. Herpin serves as board chair for the Episcopal School of Acadiana and is a board member of the Lafayette-Acadiana chapter of Legatus.

09:12 EDT Mace Security announces additional unsecured subordinated funding - Mace Security obtained a $100,000 additional unsecured subordinated loan from a Board member on May 23, 2024 with the funds to be drawn down if and as necessary. The initial draw was $20,000. The note matures on the sooner of July 27, 2025 or when the Company's senior line of credit is repaid. The note bears interest at 10% per annum. The note does not have a conversion feature.

09:07 EDT Sanofi completes acquisition of Inhibrx - Sanofi announced the completion of its acquisition of Inhibrx. The acquisition adds SAR447537 to Sanofi's rare disease pipeline, underscoring the company's commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency patients to achieve normalization of serum AAT levels with less frequent dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. The former holders of shares of Inhibrx common stock voted to approve the acquisition at a special meeting of stockholders on May 24, 2024. Upon the closing of the acquisition, former shareholders of Inhibrx became entitled to receive $30.00 per share in cash, which represents a total equity value of approximately $1.7 billion, as well as one contingent value right per share to receive $5.00 upon the achievement of a regulatory milestone. Sanofi completed its acquisition of Inhibrx through the merger of an indirect, wholly owned subsidiary of Sanofi with and into Inhibrx, with Inhibrx continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi. Prior to the closing of the acquisition, Inhibrx completed the spin-off of Inhibrx Biosciences, distributing 92% of Inhibrx Biosciences's shares to holders of shares of Inhibrx common stock as of May 17, 2024. Inhibrx Biosciences, which was a wholly owned subsidiary of Inhibrx prior to the distribution, acquired all of the assets of Inhibrx not related to SAR447537, which include INBRX-109 and INBRX-1061, as well as all Inhibrx employees, pursuant to an internal reorganization. Inhibrx continues to own the remaining 8% of Inhibrix Biosciences following the completion of the transactions. Inhibrx Biosciences began trading on the NASDAQ Global Market on May 30, 2024, under the ticker "INXB" and, beginning on May 31, 2024, will trade under the ticker "INBX". As of May 30, 2024, Inhibrx common stock will cease to be traded on the NASDAQ Global Market and will be subsequently deregistered.

09:06 EDT Airgain signs MOU with Compal Electronic for 5G Smart FWA technology, no terms - Airgain has signed a strategic Memorandum of Understanding MOU with Compal Electronic on a comprehensive plan for commercialization of a 5G Smart Fixed Wireless Access FWA technology..."Together, we are poised to redefine the standards and capabilities of wireless communication, reinforcing COMPAL's commitment to delivering state-of-the-art solutions that shape the future of connectivity."The agreement signals a major step towards enabling mass production of this transformative technology which has the potential to substantially enhance 5G customer experience and mobile network operator or MNO capabilities. Preliminary testing results indicate a performance enhancement exceeding 25% in both throughput and range when compared to conventional indoor and outdoor omnidirectional Fixed Wireless Access FWA Customer Premises Equipment CPE. The MOU commits the two companies to a collaboration which will see them evaluate the technology's 5G KPI enhancements and assess the feasibility, effectiveness, and opportunities for original equipment manufacturer and original device manufacturer ODM for FWA device development....

09:04 EDT Nokia to deliver Esports event over Wi-Fi technology - Nokia today announced it is working with several eGaming industry leaders, including SCUF and Oversight Esports, to host the Nokia Apex Legends Invitation Tournament. This is the first-ever Esports event to use Wi-Fi instead of ethernet-based connectivity. The charity event will feature 20 teams of professional and amateur players worldwide competing over Wi-Fi. Nokia's Wi-Fi Beacon 10, built on the Qualcomm(R) Networking Pro Series platforms, embeds unique latency and queuing technology to give service providers a powerful Wi-Fi gateway solution that can rival any commercial and retail device on the market. For customers, the Beacon provides the ultimate end-user experience, delivering gaming-level latency that optimizes performance. All participants in the Apex Challenge tournament will receive Nokia's Beacon Wi-Fi gateway, custom SCUF controllers and a cloud gaming subscription. Players will self-install the gateway in their homes to establish the Wi-Fi connection needed to access the game. Once online, gamers play in a "hide-and-seek" style event. The event will be streamed live by the participants on multiple platforms such as Twitch, Kick, X, and YouTube, and will feature live narration by the talented DisguisedToast and NiceWigg, two popular Apex Legends content creators and commentators.

09:03 EDT LPL Financial: Highland Partners joins broker-dealer, RIA, custodial platforms - LPL Financial announced that advisors with Highland Partners Financial Services, which is led by Managing Partner G. Mark Hamby, have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported serving more than $400 million in advisory, brokerage and retirement plan assets and join LPL from Momentum Independent Network, a subsidiary of Hilltop Holdings. Based in Glen Allen, Va., in the greater Richmond area, Hamby has more than 30 years of experience in the financial services industry and is known for fostering an entrepreneurial spirit. He founded Highland Partners in 2019 to offer a comfortable environment for like-minded advisors to follow the path of independence in serving their clients' best interests. Highland Partners currently supports financial advisors J. Michael Duke, Thomas R. Kirby, Simon M. Joseph and Elaine B. Miller in Virginia, Bernard R.Theis in Pennsylvania and Lawrence Karpf, Jean E. Albanese and Patricia E. Donelan in New Jersey, each running individual practices focused on providing families, business owners and executives with investment strategies and holistic financial planning.

09:03 EDT Edible Garden achieves high scores in PrimusGFS audit - Edible Garden announced that it achieved high scores in the Company's PrimusGFS audit and that the production, packing, and distribution of its applicable products is certified to Global Food Safety Initiative, GFSI, recognized Certification Program standards. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are delighted to have achieved top-level PrimusGFS scores, a reflection of the hard work and dedication of the Edible Garden team towards maintaining rigorous food safety standards. This achievement not only underscores our commitment to delivering the highest quality products but also reinforces our leadership in food safety, aligned with our Zero-Waste inspired mission, ensuring the efficient production and delivery of fresh, sustainable produce."

08:48 EDT Clear Secure and investing platform Public partner for identity security - Clear Secure and Public, investing platform for stocks, ETFs, crypto, options, bonds, and high-yield cash, announced a new partnership to give members the option to verify their identity with Clear when opening an investment account. Public aims to be the primary investment account for investors nationwide, through its data and tools and AI-powered research assistant Alpha. As part of this partnership, all Clear Plus Members - those who pay for Clear's subscription airport business - that sign up for a Public account will receive $100 in their Public account.

08:43 EDT Sealsq announces it will join the Japanese Interest Group - SEALSQ announced that it will support the Connectivity Standards Alliance development in Asia by joining the Japanese Interest Group, JIG. The Alliance, an international community of more than 700 technology companies committed to open standards for the Internet of Things, recently announced the creation of the Japan Interest Group. Comprised of volunteer members united by their interest in Alliance technologies and the IoT market in Japan, this newly established interest group, led by Interim Chair Alliance Member Fumi Shingai, CEO of X-HEMISTRY Inc., with the support from Interim Vice Chair Shigeki Nakamura of Panasonic, Interim Secretary Denver Mishima of Allion Japan, aims to foster dialogue and collaboration among its members while enhancing Matter and Aliro Smart Home standards globally.

08:41 EDT La Rosa Holdings acquires eleventh real estate brokerage franchisee - La Rosa Holdings announced that it has completed an acquisition transaction and now holds a 51% interest in the Company's franchisee - La Rosa Realty Success, located in Apopka, Florida. Joe La Rosa, CEO of the Company, commented, "The acquisition of Success is expected to not only increase our revenue but also enhance our margins through improved operating efficiencies and economies of scale as we integrate it into La Rosa. Prior to the acquisition, Success had 33 agents. Concurrent with the acquisition, we added 18 agents, representing a 55% increase. By offering agents a choice between a revenue share model and an annual fee-based model with 100% commissions, we anticipate an accelerated trend of agents moving from traditional high-cost brokerages to our more efficient, high-value model. We continue to grow revenue organically, and as we continue acquiring franchisees, we expect significant additional contributions to our revenue growth throughout 2024. We believe that we are well on our way towards achieving our target of an annualized revenue run rate of $100 million by the end of 2024, with profitability expected in 2025."

08:39 EDT Telomir Pharmaceuticals announces two milestone for Telomir-1 - Telomir Pharmaceuticals announced the commencement of several significant milestones. These events underscore its commitment to advancing innovative treatments to mitigate the effects of aging and the continuation of its groundbreaking work. "Beginning the telomere length and safety study, it is incredibly important for Telomir as it marks the next phase in the development of Telomir-1 and we believe should provide us with information that will help us to make progress in our efforts to combat many of the diseases of aging," said Dr. Chris Chapman, Co-Founder, Chairman, CEO, President and CMO of Telomir. These studies are potentially usable for veterinary as well as human IND purposes. "We believe the data from the canine study will provide us with pre-clinical animal testing endpoints to determine Telomir-1's potential as a treatment for age-related conditions such as gait weakness and joint damage, and will provide us with information on physical examinations, blood collection, urine collection, and telomere length." Dr. Mike Roizen, special consultant to Telomir reiterated that "the study should not only be used to support further work on benefits and risks in canines, especially those with joint disease, but also provide key information for designing studies in humans."

08:37 EDT Roadzen set to join Russell 2000, Russell 3000 indexes - Roadzen announced that the Company is set to be added to the Russell 2000, Russell 3000, and Russell Microcap Indexes as part of the annual reconstitution of the Russell stock indexes, effective at the US market open on Monday, July 1, 2024. A preliminary list of Russell 3000 Index additions, including Roadzen, was posted by FTSE Russell on May 24, 2024.

08:36 EDT AmpliTech Group regains compliance with Nasdaq listing requirements - AmpliTech Group received a notice from the Nasdaq Stock Market, stating the Company has regained compliance with Nasdaq's periodic filing requirement.

08:36 EDT Ascendis Pharma to spotlight latest updates for TransCon portfolio at ENDO 2024 - Ascendis Pharma will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston. "In addition to physician and caregiver presentations in pediatric GHD, we look forward to our first in-person opportunity to share data from foresiGHt, our pivotal trial of TransCon hGH in adults with GHD," said Aimee Shu, M.D., Ascendis Pharma's Senior Vice President of Clinical Development, Endocrine Medical Sciences. "And with World Hypoparathyroidism Day coinciding with the first day of ENDO, we are pleased to host an informational booth focused on deepening physician awareness of the significant health and quality-of-life impacts of hypoparathyroidism."

08:34 EDT Gaucho Group announces formation of Gaucho Open Asset Lending - Gaucho Group announced the formation of a new fintech mortgage lending division, Gaucho Open Asset Lending. As Gaucho Holdings' new financing arm, GOAL is intended to serve as the Company's self-financing option for buyers of its unique luxury vineyard real estate project, Algodon Wine Estates, with plans to expand beyond. This strategic development allows Gaucho Holdings, which owns Algodon Wine Estates outright, to offer self-financed mortgages to prospective buyers. These options include 10, 15, and 20-year mortgage terms, providing greater accessibility to over 400 vineyard estate lots. The Company estimates that the potential revenue from the sale of these vineyard lots could be approximately USD 80 - 100 million, excluding any future appreciation. GOAL's introduction is designed to bolster the Company's financial structure by generating significant interest income from these transactions. Even after the sale of all projected lots, Gaucho Holdings will retain over 2,500 acres for its operations and further development. Furthermore, Gaucho Holdings aims to expand GOAL beyond its own real estate projects, with the potential to disrupt the lending industry in Argentina by providing innovative fintech mortgage and lending solutions in a country where traditional financing options are largely unavailable to the public. GOAL anticipates soon launching an app to reach 46 million Argentines, focusing on highly urbanized cities such as Buenos Aires, Cordoba, Mendoza, and Rosario. These cities have substantial populations that have historically been excluded from the lending market, with limited access to mortgages and credit. The Company believes this is a timely and fitting product for Argentina, where it foresees a robust demand for lending services, particularly in urban areas with a growing need for housing and credit access.

08:33 EDT OSI Systems awarded $42M contract for screening solutions - OSI Systems was awarded a contract from an international airport for approximately $42M to provide a range of checkpoint and hold baggage screening solutions. Among the systems to be included are the RTT 110 explosive detection system for screening hold baggage, Orion 920CT checkpoint screening system integrated with Rapiscan TRS for inspecting carry-on items, and the 935DX large tunnel systems for screening air cargo and pallets. Additionally, as part of this contract, OSI Systems is also responsible for comprehensive multi-year maintenance, service, and support.

08:32 EDT Taoping wins AI-powered smart terminal contract for over $1M - Taoping received a new AI-powered Smart Terminal contract valued over $1M. The company concurrently entered a strategic cooperation agreement with Zhenjiang Fengchao Technology to accelerate market penetration of Taoping's AI-powered Smart Terminals. Taoping's recently launched enhanced AI-powered Smart Terminals leverage high-end video displays to integrate AI technology. Initially targeting advertisers, these enhanced terminals enable autonomous generation of advertising content. Under the agreement, ZFT will assist Taoping in boosting sales of its upgraded AI-powered Smart Terminals.

08:31 EDT Sharps Technology signs 5-year, $200M syringe SA with Nephron - Sharps Technology announces the signing of a 5-year, $200 million syringe Sales Agreement, SA, with Nephron Pharmaceuticals to complement the Company's Asset Purchase Agreement, APA, to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be the only fully dedicated, specialized COC prefillable syringe manufacturing plant in North America and was designed with innovative manufacturing capabilities to produce high-demand, specialty syringe systems. Product delivery is scheduled to begin late in the second quarter of 2025, with projected revenue totaling approximately $37 million for the first 12 months of sales.

08:27 EDT Sacks Parente Golf launches Weekly Performance Pool Program for PGA players - Sacks Parente Golf Company announces the launch of a Weekly Performance Pool program for players on the PGA TOUR Champions using Newton Motion driver shafts. The incentive program offers the opportunity for players on the PGA TOUR Champions to compete for prize money based on their individual performance with the Newton Motion shaft in their driver at any given tournament. Unlike traditional prize structures, participants will only compete against others within the pool, enhancing the excitement and camaraderie among players swinging a Newton Motion driver shaft. Participation in the Weekly Performance Pool is open to any player on the PGA TOUR Champions, regardless of their status. To qualify, players first notify the Company of their intent to participate in the program via a simple agreement. Then, they are confirmed to be using the Newton Motion driver shafts via Darrell Survey, the golf industry's leading independent and impartial arbiter of equipment usage. To be eligible for the Weekly Performance Pool, players must play the Newton Golf Motion shaft in their driver exclusively for all competitive rounds in a given tournament event to be eligible for the Weekly Performance Pool. Payouts will be distributed based on performance against other players in the program. In addition to the weekly payouts, Newton Golf Shafts will reward any participating player who wins an event outright with a significant bonus, as well as the first-place weekly payout. This bonus will be doubled for a PGA TOUR Champions Major Championship win, providing further incentive for players.

08:26 EDT Ocean Power completes engineering of Merrows for hot climates - Ocean Power Technologies announced it has completed the necessary engineering for Merrows, its Artificial Intelligence capable Maritime Domain Awareness Solution, to be deployed in hot climates. The engineering efforts integrated lessons learned from current and previous deployments, including in Bahrain. These efforts were necessitated by increased interest in the solution in regions such as the Middle East, Sub-Saharan Africa, and North Africa. Philipp Stratmann, CEO and President of OPT, expressed his enthusiasm about this development, stating, "In addition to our recent expansion into Latin America, we are excited to start offering services in Sub-Saharan and North Africa, and the Middle East. Offering an integrated AI solution enables our potential customers to easily integrate PowerBuoys and WAM-Vs into their operations."

08:24 EDT Duos Technologies enters three-year agreement with CPKC - Duos Technologies Group (DUOT) has entered into a three-year agreement with Canadian Pacific Kansas City (CP) allowing CPKC to use Duos developed Artificial Intelligence Solutions for mechanical inspections and cross-border velocity and efficiency. The agreement marks a significant milestone for both entities with a multi-year agreement to implement advanced AI-based models in CPKC's transnational operations. "I would like to thank CPKC for their commitment to Duos and their recognition of the Duos Railcar Inspection Portal capabilities to help them with their southern border initiative. All of us know how moving commerce across the border safely and securely is critical to our nation's economy," said Duos CEO, Chuck Ferry.

08:23 EDT Syntec Optics secures order to develop high resolution aperture lens system - Syntec Optics announced that it secured an order from an industry-leading blue chip customer to develop optical system for state-of-the-art low light digital sensors. These lenses allow more light to reach the camera sensor, thus enabling better performance in low-light conditions. Such pioneering systems require high technical challenges to design and make.

08:22 EDT Fiverr announces new partnership with Bobby Berk - Fiverr announced an exciting new partnership with interior design expert and CEO Bobby Berk. As a new brand ambassador, Bobby Berk will be featured in exclusive content featuring design tips and insights on how he and his team work and offer limited edition consultations to three individuals or businesses to transform their home or office spaces. The partnership, a Limited Edition consultation with Bobby Berk, an Emmy-winning design expert, TV host, and CEO of his eponymous design firm, will run from June 3-17, 2024 when individuals and businesses can apply online for a free, personalized, 45-minute interior design session to help transform their space.

08:20 EDT HCI Group completes 2024-2025 catastrophe reinsurance programs - HCI Group has completed its catastrophe reinsurance programs for the 2024-2025 treaty year, which runs from June 1, 2024 through May 31, 2025. Similar to the prior year, HCI secured two reinsurance towers for its insurance subsidiaries, Homeowners Choice and TypTap. Reinsurance Tower 1 covers all Homeowners Choice policies issued in Florida and Reinsurance Tower 2 is shared between TypTap and Homeowners Choice and covers all TypTap policies and Homeowners Choice policies issued outside of Florida. Across its two reinsurance towers, HCI secured over $2.7 billion in aggregate limit for the 2024-2025 treaty year. All of HCI's private reinsurers are AM Best rated 'A-' or better or have fully collateralized their obligations to HCI. HCI's reinsurance retentions are similar to the prior year, including a retention of $14 million for Reinsurance Tower 1 and $9 million for Reinsurance Tower 2. The reinsurance retentions apply to each of a first and second event. For Reinsurance Towers 1 and 2, HCI Group expects to incur net consolidated reinsurance premiums ceded to third parties, excluding Claddaugh, of approximately $333.6 million from June 1, 2024 through May 31, 2025, assuming no losses occur during that period. HCI's reinsurance premiums are an estimate based on exposure projections and subject to true up at September 30, 2024.

08:19 EDT NV5 Global awarded $14M in utility geospatial, vegetation management contracts - NV5 Global announced that it has been awarded $14M in contract wins by utilities to support asset management and vegetation management of electrical transmission and distribution grid infrastructure. "Electrification initiatives and the expansion of energy-intensive facilities such as data centers have put unprecedented capacity requirements on the nation's electrical grid," said Dickerson Wright, PE, Executive Chairman of NV5. "NV5 scans approximately 100,000 miles of utility transmission and distribution lines each year to assist utilities with meeting the growing demand for electrical service, and the increased adoption of geospatial data for utility infrastructure improvements continues to accelerate organic growth in NV5's utility geospatial segment."

08:18 EDT Tonix Pharmaceuticals announces two poster presentations of TNX-102 SL - Tonix Pharmaceuticals announced two poster presentations at the American Society of Clinical Psychopharmacology, ASCP, Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. In the poster presentation titled, "Effect of Bedtime Sublingual Cyclobenzaprine on Pain, Sleep, Fatigue, and Cognition in Fibromyalgia-Type Long COVID: Results of a Double-Blind Randomized Proof-of-Concept Phase 2 Study," TNX-102 SL showed a robust effect size of 0.5 in improving fatigue and showed consistent activity across secondary measures of sleep quality, cognitive function, disability and Patient Global Impression of Change, but did not meet the primary endpoint of multi-site pain reduction at Week 14.TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed. In the poster presentation titled, "Optimizing Acute Stress Reaction Interventions with TNX-102 SL - The OASIS Trial: Sustaining Civilian Performance Post-Trauma by Reduction of ASR and Prevention of ASD/PTSD," TNX-102 SL will be evaluated for the reduction in severity of acute stress reaction and the frequency of acute stress disorder and posttraumatic stress disorder in civilians after a motor vehicle collision.

08:15 EDT CMC Metals plans to initiate studies of dense media separation, ore sorting tech - CMC Metals announced that the Company hopes to soon initiate studies to examine the viability of utilizing dense media separation or ore sorting technologies at the Silver Hart Project. Dense Media Separation has emerged as a powerful mineral processing technique as it enables the separation of minerals based on their specific gravity, offering a highly efficient method to pre-concentrate valuable minerals while discarding unwanted gangue materials. This separation process occurs through the use of heavy liquids with specific densities, setting the stage for a wide range of applications across various mining sectors. As mining companies adopt DMS and similar technologies, they contribute to a more sustainable and responsible mining industry. Ore sorting has been proven to provide both economic and environmental benefits to mining projects, while increasing the overall efficiency and productivity of the mineral processing system.

08:12 EDT Vast receives planning consent for CSP-powered Solar Methanol Project - Vast has received planning consent for Solar Methanol 1, a CSP-powered reference plant that will produce green fuels. SM1 will be located in Port Augusta, South Australia and will have the capacity to produce 7,500 tonnes per annum of green methanol, one of the most versatile hydrogen derivatives which, if produced using Vast's CSP technology, has the potential to decarbonise shipping and is already being used to power major container vessels. The project supports South Australia's push to develop a domestic hydrogen industry and, if successful, could create an important pathway for scalable green fuel production that is not dependent on limited biomass resources. Craig Wood, CEO of Vast, said: "Planning consent is an important milestone for this major project for Port Augusta and South Australia. SM1 will produce low-cost green fuels, which can play an important role in decarbonising the global maritime industry. The combination of technologies can be scaled rapidly, acting as a catalyst for a green fuels industry in Australia and around the world."

08:09 EDT Olink announces publication of study using Olink Explore - Olink Holding reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention.

08:08 EDT INmune Bio to join Russell 3000 Index - INmune Bio is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

08:07 EDT Krispy Kreme names Atiba Adams chief legal officer - Krispy Kreme (DNUT) announced that Atiba Adams will join the company as chief legal officer effective June 25. Adams will report to Josh Charlesworth, President and Chief Executive Officer of Krispy Kreme. Adams brings more than 20 years of legal experience most recently at Bausch + Lomb (BLCO), where he served as Senior Vice President and Deputy General Counsel.

08:05 EDT Microchip adds 12 new products to wireless portfolio for Bluetooth integration - System designers face many barriers when adding Bluetooth functionality to their products, from skill and resource limitations to budget constraints to time-to-market pressures to challenging performance and integration requirements. Microchip Technology has expanded its Bluetooth Low Energy portfolio with 12 new products, aimed at providing designers with an extensive array of choices to tackle their unique challenges, effectively lowering barriers across designs spanning from the simplest to the most advanced. These additions include the RF-ready WBZ350 module and the PIC32CX-BZ3 SoC that offers the lowest entry point available for integrating a Bluetooth Low Energy microcontroller into product designs. In addition to its Bluetooth MCUs, Microchip introduced the RNBD350 plug-and-play module that reduces the cost and complexity barriers to adding Bluetooth Low Energy connectivity to product designs. These modules minimize the time, money and engineering resources required for RF design optimization, regulatory certification and software development. For experienced engineers who are looking for more flexibility, Microchip offers robust wireless, multi-protocol MCU System-on-Chip options.

08:04 EDT NaaS announces plan to implement ADS ratio change - NaaS Technology announced that it plans to change the ratio of its American Depositary Shares to its Class A ordinary shares, par value $0.01 per share, from the current ADS Ratio of one ADS to 10 Class A ordinary shares to a new ADS Ratio of one ADS to 200 Class A ordinary shares. For the company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-twenty reverse ADS split. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with the SEC to reflect the change in the ADS Ratio. The company anticipates that the change in the ADS Ratio will be effective on or about June 10, 2024.

08:04 EDT Lightbridge CEO attends White House Summit on domestic nuclear deployment - Lightbridge Corporation announced that its Chairman and CEO, Seth Grae, attended the White House Summit on Domestic Nuclear Deployment, hosted by the Biden-Harris Administration. The Summit, held on May 29, 2024, focused on new initiatives to strengthen the domestic nuclear industry and advance America's clean energy future. The White House Summit underscored the Administration's commitment to bolstering the nuclear sector as a cornerstone of the nation's strategy to achieve net-zero emissions and enhance energy security. Key announcements included measures to support nuclear innovation, ensure the longevity of existing reactors, and promote the development of advanced nuclear technologies. The White House Summit brought together leaders from the nuclear industry, government, and academia to discuss the role of nuclear energy in the United States' energy policy. Mr. Grae's participation highlights Lightbridge's active engagement in national discussions aimed at promoting nuclear energy as a critical component of a sustainable and secure energy landscape. The collaborative efforts and new policies announced are expected to drive significant advancements in nuclear technology, fostering a robust and resilient energy infrastructure.

08:03 EDT Momentus secures contract from DARPA - Momentus has secured a contract from the Defense Advanced Research Projects Agency, or DARPA, aimed to support the design and in-space demonstration of technologies that will enable the construction of large-scale structures in space. The program, known as DARPA Novel Orbital and Moon Manufacturing, Materials, and Mass-efficient Design, or NOM4D, focuses on developing the foundations for building robust and precise structures in space. The vision is to transport raw materials from Earth for in-orbit manufacturing. Unlike deployable structures optimized for ground tests and launch survival, these structures-such as solar arrays, antennas, and optics-will be specifically designed for the space environment. This exciting endeavor represents a significant step toward advancing Momentus' capabilities in space construction and utilization. Under the recently awarded "NOM4D On-Orbit Demo" program, Momentus will collaborate with other NOM4D performers to design and refine experiments that can be integrated onto the Momentus Vigoride Orbital Service Vehicle. These experiments must meet the stringent requirements for both launch and in-space operation.

08:02 EDT Broadridge acquires AdvisorTarget, terms not disclosed - Broadridge Financial Solutions announced that it has acquired AdvisorTarget, a company providing asset management and wealth management firms with data products to help power digital marketing, sales and engagement programs targeting financial advisors. Adding AdvisorTarget's unique advisor insight to Broadridge's existing data and analytics suite will enable asset managers to better target advisors and drive their growth strategies.

07:47 EDT Jacobs to design wastewater treatment plant expansion in Hamilton, Ontario - Jacobs was contracted by the City of Hamilton, Ontario in Canada to provide engineering services for the Woodward Avenue Wastewater Treatment Plant Phase 2 Expansion. The project will upgrade and expand the city's largest wastewater treatment plant to meet projected population growth and improve water quality in the area. At an estimated capital cost of approximately $310M, the Phase 2 Expansion is one of the city's largest wastewater infrastructure projects and a critical part of its Clean Harbour Program to improve environmental health in Hamilton Harbour - a bay located at the western tip of Lake Ontario. The project will increase the average rated capacity of the facility from 409 to 500 million liters per day.

07:42 EDT PyroGenesis to exercise options for 50% stake in HPQ Silica Polvere - HPQ Silicon announces receipt of a notice from PyroGenesis Canada with intent to immediately exercise the right to convert its 10% gross sales royalty into a 50% ownership of HPQ Silica Polvere, a wholly-owned subsidiary of HPQ. The primary focus of HPQ Polvere is its Fumed Silica Reactor project. PyroGenesis is developing proprietary technology for this initiative, which efficiently converts quartz into fumed silica. As previously discussed in the Company's news releases dated July 6, 2021, HPQ Polvere and PyroGenesis entered a development agreement covering the Fumed Silica Reactor development program and future commercialisation of fumed silica materials made with this green, proprietary and low-cost manufacturing process. The Agreement also granted PyroGenesis the right to convert, at any time, its rights to an annual royalty on the gross sales generated by HPQ Polvere, into an ownership stake in that company. In accordance with the Agreement, and with this notice, HPQ and PyroGenesis will proceed to negotiate and draft a shareholders' agreement.

07:37 EDT Xeris announces XeriSol data formulated once-weekly SC levothyroxine - Xeris Biopharma Holdings announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the company's XeriSol formulation technology to enable a novel once-weekly SC injection of levothyroxine. This novel formulation significantly increases the bioavailability of levothyroxine reducing overall drug exposure and enabling a dosing regimen with the potential to mitigate the many challenges associated with achieving and maintaining a normal level of thyroid stimulating hormone TSH with daily oral formulations of levothyroxine. ..."A 2022 study published in the Journal of the Endocrine Society estimated the prevalence of hypothyroidism in the U.S. grew to 11.7% or approximately 30 million adults in 2019*. Innumerable reports have been published documenting the various compliance and absorption challenges that can interfere with the bioavailability of oral levothyroxine. Interestingly, in our own Phase 2 study, 40% of patients considered stable at the time of screening were found to have their TSH or T4 outside of normal range. We believe our once-weekly SC injection can enable control in patients who struggle with oral preparations for a variety of reasons," said Paul R. Edick, Xeris' Chairman and CEO. "We are excited by the initial top-line results of our Phase 2 dose-finding study of XP-8121. These results are further evidence of our target dose conversion and consistent with the estimates generated from the prior Phase 1 study in healthy volunteers," said Kenneth E. Johnson, PharmD, Xeris' Senior Vice President, Global Development and Medical Affairs. "Given the known challenges of oral bioavailability of levothyroxine and further by the high rate of screen failures observed in our phase 2 study, we believe that XP-8121 could fill a substantial unmet medical need. We look forward to meeting with the FDA later this year and expect to present complete study results at upcoming medical meetings as well as submission to peer-reviewed medical journals."

07:36 EDT Reunion Gold enters option agreement to acquire Majorodam Project - The Company has entered into an option agreement to acquire the Majorodam Project in Suriname, which comprises a right of exploitation for gold over an area totaling 99.85 square kilometers. The project is located along a paved road 120 km south of Paramaribo, the capital city of Suriname and "on trend" about 12 km south of the 1.02 Moz @ 2.2 g/t Au Saramacca deposit owned by Zijin Mining. The Majorodam project is prospective for an orogenic gold system and has a similar geologic setting to that of Oko West. Except for airborne geophysics and surface mapping and limited geochemical sampling, there has been little modern exploration work completed at Majorodam. The project area covers the NE trending contact between granitic and volcanic rock units, with the latter unit creating a prominent topographic high. The airborne magnetic survey indicates the presence of several significant NE trending structures in the project area and active alluvial gold mining is occurring in the streams draining the main topographic ridge comprised of greenstone altered volcanic units. The option agreement is valid for an initial period of six years and requires the Company to make option payments of $150,000 following execution of the agreement and $75,000 on each of the second, third, fourth and fifth anniversary, and to incur minimum exploration expenditures starting with $200,000 during each of the first two years. It is expected that this project will be transferred to Greenheart Gold in connection with the proposed business combination between Reunion Gold and G Mining Ventures.

07:32 EDT Incannex announces patient dosing commenced in Phase 2/3 trial of IHL-42X - Incannex Healthcare announces that patient dosing has commenced in the Company's Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea. IHL-42X is the Company's proprietary fixed dose combination drug for treatment of obstructive sleep apnea. Commencement of patient dosing in the United States represents a significant milestone in its development. Initiating dosing in the trial follows the opening of an Investigational New Drug application with the FDA and a Phase 2A study completed in 2022 whereby Incannex observed IHL-42X to reduce the apnea hypopnea index, the standard measure of OSA, by an average of greater than 50% at the low dose in the study.

07:23 EDT Kohl's falls 23% to $21.00 after Q1 results, FY24 guidance miss estimates

07:14 EDT Li-Cycle teams with Daimler Truck N.A. recycling lithium-ion batteries - Li-Cycle Holdings is proud to support Daimler Truck North America DTNA on its goal to integrate a comprehensive circular economy approach across its operations to reduce its carbon footprint. Li-Cycle and DTNA have a partnership to recycle lithium-ion batteries from DTNA electric vehicles that reach the end of their life cycle. Recycling lithium-ion batteries is part of DTNA's plans to maximize battery lifespans and reduce material waste to tackle global sustainability challenges. DTNA's strategy emphasizes repairing, remanufacturing, repurposing, and recycling lithium-ion battery materials. "We are proud to partner with companies such as DTNA to support their sustainability and carbon reduction goals," said Ajay Kochhar, Li-Cycle President and CEO. "Our environmentally friendly and safe recycling technologies can recover critical materials to help create a domestic closed-loop battery supply chain, giving new life to these battery materials and helping power the world's transition to clean energy."

07:13 EDT Lantronix to showcase out-of-band management solutions at Cisco Live - Lantronix will do live demos of its AI-driven out-of-band management solutions at booth 4875 at Cisco Live held June 2-6, 2024, in Las Vegas. Its innovative solutions for out-of-band environments utilize rules-based AI to recover and mitigate network infrastructure automatically, including reliable and secure access to remote gear during an outage. The solution automates many routine tasks that can unnecessarily consume a network admin's day.

07:12 EDT Fortrea Holdings introduces solution to improve diversity in clinical trials - Fortrea announced its comprehensive and integrated solution to improve the diversity and inclusion of participants in clinical trials. Fortrea's D&I solution is designed to expand patient access to participate in clinical trials and address the U.S. Food and Drug Administration requirements, under The Food and Drug Omnibus Reform Act, to increase enrollment of underrepresented populations in clinical trials. Fortrea's comprehensive process integrates five components of diversity action planning and execution: Real-world evidence advisors research relevant real-world data sets to inform diversity planning. Regulatory, development and clinical operational experts design the Diversity Action Plan, validate with patient groups and negotiate with regulators. Operational teams access multiple data platforms, Fortrea's Site Advisory Board and technology-enabled solutions to implement the Diversity Action Plan as an integral part of Fortrea's clinical trial execution. Monitoring and reporting are enabled by Fortrea's exclusive Diversity and Inclusion Study Insights Dashboard, providing actionable data and visualizations for ongoing study management. Experienced report technical writers compile data and prepare reports for regulatory submission, with ongoing regulatory support provided as part of the D&I solution.

07:11 EDT Compugen to receive $5M milestone payment from AstraZeneca - Compugen (CGEN) is entitled to receive a $5M milestone payment from AstraZeneca (AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The trial is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab deruxtecan, AstraZeneca and Daiichi Sankyo's (DSNKY) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo. The ARTEMIDE-Biliary01 Phase 3 trial is evaluating the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in patients with biliary tract cancer after surgical resection with curative intent.

07:10 EDT Dollar General sees FY24 CapEx $1.3B-$1.4B - In order to better optimize the planned capital expenditures for fiscal year 2024 and to expand the investment in mature stores, the company is increasing the number of store remodels and reducing the number of expected new store openings, resulting in an overall net increase in the number of total expected real estate projects for the year. The company now expects to execute 2,435 real estate projects, including 730 new store openings, 1,620 remodels, and 85 store relocations, which compares to its previous expectation of 2,385 real estate projects in fiscal 2024, including 800 new store openings, 1,500 remodels, and 85 store relocations. "While it is still early in our fiscal year, we are encouraged by our first quarter financial results," said Kelly Dilts, Dollar General's CFO. "Although we are experiencing shrink and sales mix headwinds that are greater than we had initially anticipated coming into the year, we are working to mitigate the impact of these challenges and are reiterating our full-year financial guidance as we remain focused on our goal of delivering consistent, strong financial performance."

07:09 EDT Armlogi Holding announces expansion at Port of Savannah - Armlogi Holding announced the signing of a lease for a new 733,200 square foot warehouse located close to the Port of Savannah in Georgia. The Port of Savannah's strategic location makes it an ideal transit point connecting the United States and global markets, providing cross-border e-commerce companies from Asia with direct access to endmarkets, and accessing 65 percent of the U.S. population within a two-day drive by ground, water, rail or air. Aidy Chou, Chairman and CEO of Armlogi, commented, "We are thrilled to expand our operations to the Port of Savannah, a critical hub for logistics and supply chain solutions in the United States. This new warehouse will significantly enhance our capacity to serve our clients with even greater efficiency and speed."

07:08 EDT Best Buy sees Q2 comparable sales down 3% - Bilunas continued, "For Q2 FY25, we expect comparable sales to decline by approximately 3% and our non-GAAP operating income rate to be approximately 3.5%."

07:07 EDT Beamr Imaging announces improved tiered pricing model - Beamr Imaging announced an improved tiered pricing model, including a customizable plan for enterprises, that will offer customers enhanced security and privacy features, a plan with incentives for long-term contracts and a prepaid plan. The plan for long-term contracts offers incentives for usage growth for customers who wish to easily optimize a constant flow of new videos. The prepaid plan is suitable for users with specific, flexible video needs.

07:06 EDT Monte Rosa Therapeutics announces leadership team promotions - Monte Rosa Therapeutics announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.

07:04 EDT Village Farms boosts ownership of Rose LifeScience - Village Farms International announces it has increased its ownership of Quebec-based Rose LifeScience by 10% to hold an 80% interest. "Village Farms' initial 70% acquisition of Rose stands out as one of the most complementary business combinations to date in the Canadian cannabis industry. Since late 2021, the combination of the experienced teams at Rose and Pure Sunfarms have driven Village Farms into the number two share rank nationally as Rose sales grew more than 300% to reach the number two share rank in Quebec, with each closing the gap to number one," said Michael DeGiglio, President and Chief Executive Officer, Village Farms.

07:04 EDT Brookfield Renewable Partners enters negotiations to acquire majority in Neoen - Brookfield (BAM), together with its institutional partners including Brookfield Renewable (BEP) and Temasek, through a special purpose vehicle exclusively controlled by Brookfield, has entered into exclusive negotiations to purchase a 53.32% shareholding in Neoen, a global renewable energy developer headquartered in France, from Impala, the Fonds Strategique de Participations - FSP -, Cartusia and Xavier Barbaro, and other shareholders at a price per share of EUR39.85. Following the block acquisition, Brookfield Renewable Holdings would file a mandatory cash tender offer for the remaining shares and outstanding convertible bonds or OCEANEs in Neoen at a price of EUR39.85 per share and at a price per OCEANEs issued in 2020 and 2022 in line with the offer price for the shares and the terms of each OCEANE. Neoen is a global renewables developer with an 8,000 megawatt high-quality portfolio of wind, solar and storage assets in operation or under construction alongside a significant 20,000 megawatts advanced pipeline of development projects, located in strategic markets, particularly in Australia, France and the Nordics. Neoen has significant expertise in battery storage technology. Brookfield sees the investment in Neoen as an opportunity to scale Neoen's portfolio of assets in a context of accelerating clean power demand. Brookfield is pursuing the transaction through the Brookfield Global Transition Fund II. Brookfield Renewable, the largest investor in the Brookfield Global Transition Fund II, expects to invest up to EUR500M in the acquisition, which will be funded through available liquidity. It is expected that the regulatory approvals would be obtained by Q4 2024 and that the tender offer would be launched in Q1 2025. The Board of Directors of Neoen unanimously welcomed the proposed transaction without prejudice to the reasoned opinion to be issued by the Board following the submission of the report of the independent expert.

06:35 EDT Clean Energy signs fueling agreement with Cemex US in Southern California - Clean Energy and Cemex, a company within the building materials industry, have announced a new fueling agreement to provide ultra-clean renewable natural gas to power 39 of Cemex US's ready-mix and cement bulk trucks in Southern California. Cemex's collaboration with Clean Energy is the latest addition to its lower-carbon fuels portfolio for its California fleet. Forecasted to provide approximately 300,000 gallons of RNG annually, the fleet will utilize Clean Energy's public station network in Southern California to fuel with RNG, a negative carbon-intensity transportation fuel that substantially lowers greenhouse gas emissions by an average of 300% versus diesel. Alongside the new fueling deal, Clean Energy will commission a private fueling station exclusively for Cemex's growing RNG fleet. Located in Rialto, CA, the new station will include time-fill dispensers and a dedicated fast-fill dispenser. The construction project is expected to be completed by the end of this year and Cemex trucks will begin fueling on-site soon after. Clean Energy will be supplying RNG to the new private station, as well as operating and maintaining the site upon completion. Clean Energy currently has a network of over 600 fueling stations around North America.

06:26 EDT Brookfield enters exclusive negotiations to buy majority stake in Neoen - Brookfield (BAM), together with its institutional partners including Brookfield Renewable (BEP) and Temasek, through a special purpose vehicle exclusively controlled by Brookfield, has entered into exclusive negotiations to purchase a 53.32% shareholding in Neoen (NOSPF), a global renewable energy developer headquartered in France, from Impala (IMPUY), the Fonds Strategique de Participations, Cartusia and Xavier Barbaro, and other shareholders at a price per share of 39.85 euros. Following the block acquisition, Brookfield Renewable Holdings would file a mandatory cash tender offer for the remaining shares and OCEANEs in Neoen at a price of 39.85 euros per share and at a price per OCEANEs issued in 2020 and 2022 in line with the offer price for the shares and the terms of each OCEANE. Connor Teskey, CEO, Renewable Power & Transition at Brookfield Asset Management, said: "Under Impala's sponsorship, Neoen has built one of the world's greatest renewable energy development platforms. We are excited to build on Brookfield's expertise, track-record and access to capital to further accelerate Neoen's growth while preserving its culture and identity. Acquiring Neoen further strengthens Brookfield's global scale, while diversifying into key renewables markets and adding expertise in battery storage technology. We look forward to partnering with management to scale-up the business to meet the growing demand we are seeing for clean power." Reference Link

06:12 EDT UBS announces changes to group executive board - UBS announced the next significant milestones in UBS's integration of Credit Suisse are the merger of UBS AG and Credit Suisse AG, which takes place on May 31, and the move to a single Intermediate Holding Company in the U.S. in June. UBS announces the following changes to its Group Executive Board, effective July 1: Iqbal Khan will assume the role of President UBS Asia-Pacific, effective 1 September 2024, and become Co-President GWM. Rob Karofsky will become President UBS Americas and Co-President GWM. George Athanasopoulos and Marco Valla will join the GEB as Co-Presidents of the Investment Bank. Damian Vogel will be appointed Group Chief Risk Officer and become a member of the GEB, succeeding Christian Bluhm. Stefan Seiler, Head Group Human Resources and Corporate Services, will expand his responsibility to include Group Communications and Branding led by Marsha Askins. Ulrich Korner, CEO of Credit Suisse AG, will step down from the GEB at the end of June following the merger of the parent banks UBS AG and Credit Suisse AG. He will retire from UBS later this year. Edmund Koh, President UBS Asia-Pacific, will step-down from the GEB effective September 1. Naureen Hassan, Regional President UBS Americas, has decided to retire from UBS, effective July 1. Reference Link

06:07 EDT Royal Bank of Canada raises quarterly dividend 3% to C$1.42 per share - Royal Bank of Canada announced that its board of directors has declared an increase to its quarterly common share dividend of four cents, or 3%, to C$1.42 per share, payable on and after August 23 to common shareholders of record at the close of business on July 25.

06:04 EDT Rockwell Medical names Tim Chole as Chief Commercial Officer - Rockwell Medical announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the company's President and CEO, Dr. Mark Strobeck. Chole joined Rockwell Medical in December 2019 as SVP, Sales and Marketing. In November 2022, following the company's new business strategy announcement, Chole led Rockwell's commercial organization and supported the company's vision to focus its efforts on enhancing its revenue-generating businesses and driving the company towards profitability.

05:37 EDT Mastercard opens European Cyber Resilience Centre in Belgium - Mastercard announced the opening of its European Cyber Resilience Centre, or ECRC, at its European Headquarters reaffirming the company's commitment to combatting cyber threats. The new center will sharpen defenses against cyber threats, speed up response times and serve as a hub for thought leadership in cybersecurity, fostering collaboration between the public and private sectors.

05:26 EDT Amazon, Grubhub partner on restaurant delivery - Amazon (AMZN) and Grubhub (JTKWY) announced they are partnering to make restaurant delivery to customers' doors more convenient and affordable. Starting immediately, Amazon customers in the U.S. can order from hundreds of thousands of restaurants in all 50 states with Grubhub directly on Amazon.com and in the Amazon Shopping app. Additionally, as long as a customer remains a Prime member, they can enjoy a free ongoing Grubhub+ membership worth $120 a year, without automatically renewing into a paid Grubhub+ membership. Grubhub+ includes $0 delivery fees on eligible orders over $12, lower service fees, 5% credit back on pick-up orders, and exclusive offers.

05:18 EDT Logitech expands designed-for-Mac portfolio - Logitech (LOGI) announced a new lineup of Logi for Mac products aimed at enhancing the experience for Mac users while enabling more sustainable lifestyles without compromise. Adding in the latest MX series and ergonomic innovations, the lineup includes MX Keys S for Mac, MX Keys S Combo for Mac, MX Anywhere 3S for Mac, MX Keys Mini for Mac and Ergo Series Wave Keys for Mac, a new ergo keyboard. These solutions are tailored to improve performance, productivity and comfort at the desk, catering to the diverse needs of users across macOS and iPadOS with dedicated macOS keyboard layouts and colors that complement the Apple (AAPL) ecosystem.

05:09 EDT Burning Rock Biotech enters collaboration with Bayer to develop cancer medicine - Burning Rock (BNR) has recently announced a collaboration with Bayer (BAYRY) to develop next-generation sequencing, or NGS-based companion diagnostic assays, or CDx, aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.